Theravance Biopharma is winding down its R&D operations and cutting half its workforce after its Phase 3 CYPRESS study of ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy patients failed to meet its primary endpoint. The restructuring is expected to reduce operating expenses by 60% relative to 2025 levels.
